Evidence map›Paper›PMID 31509304›Full record

ArticleEuropean journal of neurology2020

Genetic and phenotypic characterization of NKX6-2-related spastic ataxia and hypomyelination.

V Chelban, M Alsagob, K Kloth, A Chirita-Emandi, J Vandrovcova, R Maroofian, I Davagnanam, S Bakhtiari, M D AlSayed, Z Rahbeeni and 28 more

Open access · hybridAbstract read
In one paragraph

Article in European journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. A NovelInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. A novel missense mutation inFrontiers in psychiatry · 2024
    Article
  7. Article
  8. Article
  9. Emerging cellular themes in leukodystrophies.Frontiers in cell and developmental biology · 2022
    Review
  10. A NovelGenes · 2021
    Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 12 institutions in 8 countries.

V ChelbanDepartment of Neuromuscular Diseases, University College London Institute of Neurology, London, UK.ORCID 0000-0002-5817-6290
M AlsagobDepartment of Genetics, KFSHRC, Riyadh, Saudi Arabia.
K KlothInstitute of Human Genetics, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
A Chirita-EmandiGenetics Department, University 'Victor Babes', Timisoara, Romania.
J VandrovcovaDepartment of Neuromuscular Diseases, University College London Institute of Neurology, London, UK.
R MaroofianGenetics Research Centre, Molecular and Clinical Sciences Institute, St George's University of London, London, UK.
I DavagnanamBrain Repair and Rehabilitation, University College London Institute of Neurology, London, UK.
S BakhtiariBarrow Neurological Institute, Phoenix Children's Hospital, Phoenix, AZ, USA.
M D AlSayedMedical Genetics, KFSHRC, Riyadh, Saudi Arabia.
Z RahbeeniMedical Genetics, KFSHRC, Riyadh, Saudi Arabia.
H AlZaidanMedical Genetics, KFSHRC, Riyadh, Saudi Arabia.
N T MalintanClinical and Experimental Epilepsy, University College London Institute of Neurology, London, UK.
J JohannsenDepartment of Paediatrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
S EfthymiouDepartment of Neuromuscular Diseases, University College London Institute of Neurology, London, UK.
E Ghayoor KarimianiGenetics Research Centre, Molecular and Clinical Sciences Institute, St George's University of London, London, UK.
K MankadGreat Ormond Street Hospitals, London, UK.
S A Al-ShahraniMedical Genetics, KFSHRC, Riyadh, Saudi Arabia.
M Beiraghi ToosiDepartment of Paediatric Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
M AlShammariDepartment of Genetics, KFSHRC, Riyadh, Saudi Arabia.
S GroppaDepartment of Neurology and Neurosurgery, Institute of Emergency Medicine, Chisinau, Moldova.
N A HaridyDepartment of Neuromuscular Diseases, University College London Institute of Neurology, London, UK.
L AlQuaitDepartment of Genetics, KFSHRC, Riyadh, Saudi Arabia.
A QariMedical Genetics, KFSHRC, Riyadh, Saudi Arabia.
R HumaMedical Genetics, KFSHRC, Riyadh, Saudi Arabia.
M A SalihNeurology Division, Department of Pediatrics, College of Medicine, King Saud University KFSHRC, Riyadh, Saudi Arabia.
R AlmassDepartment of Genetics, KFSHRC, Riyadh, Saudi Arabia.
F B AlmutairiDepartment of Genetics, KFSHRC, Riyadh, Saudi Arabia.
M H HamadNeurology Division, Department of Pediatrics, College of Medicine, King Saud University KFSHRC, Riyadh, Saudi Arabia.
I A AlorainyDepartment of Radiology & Medical Imaging, College of Medicine, King Saud University KFSHRC, Riyadh, Saudi Arabia.
K RamzanDepartment of Genetics, KFSHRC, Riyadh, Saudi Arabia.
F ImtiazDepartment of Genetics, KFSHRC, Riyadh, Saudi Arabia.
M PuiuGenetics Department, University 'Victor Babes', Timisoara, Romania.
M C KruerBarrow Neurological Institute, Phoenix Children's Hospital, Phoenix, AZ, USA.
T BierhalsInstitute of Human Genetics, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
N W WoodDepartment of Neuromuscular Diseases, University College London Institute of Neurology, London, UK.
D ColakDepartment of Biostatistics, Epidemiology and Scientific Computing, KFSHRC, Riyadh, Saudi Arabia.
H HouldenDepartment of Neuromuscular Diseases, University College London Institute of Neurology, London, UK.
N KayaDepartment of Genetics, KFSHRC, Riyadh, Saudi Arabia.
King Faisal Specialist Hospital & Research Centre · SAUniversity College London · GBUniversität Hamburg · DEBarrow Neurological Institute · USInstitutul Oncologic din Republica Moldova · MDKing Saud University · SASt George's, University of London · GBVictor Babeș University of Medicine and Pharmacy Timișoara · ROAssiut University Hospitals · EGEpilepsy Research UK · GBGreat Ormond Street Hospital · GBMashhad University of Medical Sciences · IR

Funding

Genomic Insights into the Neurobiology of Cerebral PalsyR01NS106298 · NINDS · UNIVERSITY OF ARIZONA · PI KRUER, MICHAEL C · 2019 to 2023
$3.7M
Molecular mechanisms of mitochondrial dysfunction in ATP13A2-associated neurodegeK08NS083739 · NINDS · UNIVERSITY OF ARIZONA · PI KRUER, MICHAEL C · 2013 to 2017
$869k
Ataxia UKBritish Neurological Surveillance Unit (BNSU)Deanship of Scientific Research, King Saud University, Riyadh RGP-VPP-301KACST Grant 14-MED2007-20KFSHRC seed grant RAC#2120022Medical Research Council G0802760Medical Research Council G1001253Medical Research Council MR/J004758/1Medical Research Council MR/S01165X/1National Institute for Health Research (NIHR)NIH NINDS NS083739NINDS NIH HHS K08 NS083739NINDS NIH HHS R01 NS106298Wellcome TrustWellcome Trust WT093205MAWellcome Trust WT104033/Z/14/Z
6 · The paper itself

Abstract

background and purposeHypomyelinating leukodystrophies are a heterogeneous group of genetic disorders with a wide spectrum of phenotypes and a high rate of genetically unsolved cases. Bi-allelic mutations in NKX6-2 were recently linked to spastic ataxia 8 with hypomyelinating leukodystrophy.

methodsUsing a combination of homozygosity mapping, exome sequencing, and detailed clinical and neuroimaging assessment a series of new NKX6-2 mutations in a multicentre setting is described. Then, all reported NKX6-2 mutations and those identified in this study were combined and an in-depth analysis of NKX6-2-related disease spectrum was provided.

resultsEleven new cases from eight families of different ethnic backgrounds carrying compound heterozygous and homozygous pathogenic variants in NKX6-2 were identified, evidencing a high NKX6-2 mutation burden in the hypomyelinating leukodystrophy disease spectrum. Our data reveal a phenotype spectrum with neonatal onset, global psychomotor delay and worse prognosis at the severe end and a childhood onset with mainly motor phenotype at the milder end. The phenotypic and neuroimaging expression in NKX6-2 is described and it is shown that phenotypes with epilepsy in the absence of overt hypomyelination and diffuse hypomyelination without seizures can occur.

conclusionsNKX6-2 mutations should be considered in patients with autosomal recessive, very early onset of nystagmus, cerebellar ataxia with hypotonia that rapidly progresses to spasticity, particularly when associated with neuroimaging signs of hypomyelination. Therefore, it is recommended that NXK6-2 should be included in hypomyelinating leukodystrophy and spastic ataxia diagnostic panels.

Indexed as

Intellectual DisabilityMuscle SpasticityOptic AtrophySpinocerebellar AtaxiasChildHomeodomain ProteinsHumansMutationPhenotypeHomeodomain ProteinsNKX6-2 protein, humanhypomyelinationleukodystrophyNKX6-2spastic ataxia 8SPAX8

Identifiers

PMID31509304
PMCPMC6946857
OpenAlexW2972851084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.